GW Pharmaceuticals PLC (GWPH) 銘柄情報

https://www.jazzpharma.com/comp_announcements/transforming-together-what-our-recent-acquisition-means-for-patients-and-our-people/#:~:text=Today%20is%20an%20exciting%20and,of%20regulatory%20approved%20cannabinoid%20medicines.

do you know what happen to $GWPH ????? anyone ?????

https://www.benzinga.com/news/earnings/21/11/24060763/you-ask-we-analyze-why-sundial-growers-stock-could-slam-short-sellers $GWPH

Interesting comparison......I did the same thing with GWPH @ 67.00 a share versus TRTC @ .67 CENTS..............BACK IN 2016

NEEDLESS TO SAY GWPH IS STILL THE WINNER IMHO

$GWPH https://newrepublic.com/article/162594/marijuana-legalization-dc-biden-harris-rider

Better Buy: Medical Marijuana vs. GW Pharmaceuticals
$GWPH vs $MJNA

https://www.fool.com/investing/2019/04/03/better-buy-medical-marijuana-vs-gw-pharmaceuticals.aspx

got them yesterday

Anyone have any idea of when the Jazz shares and cash will be distributed to GWPH shareholders?

$gwph 215.25 ^ 0.1 (0.05%)
Volume: 796,181 @03/19/21 4:43:07 PM EDT

These stocks just keep going up and down and up and down. Go figure.s

$gwph $213.81 ^ 0.89 (0.42%)
Volume: 602,467 @02/19/21 6:09:38 PM EST

GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress

Total revenue for the quarter ended December 31, 2020 was $148.2 million compared to $109.1 million for the quarter ended December 31, 2019.

Total revenue for the full-year 2020 was $527.2 million, a 69 percent increase compared to $311.3 million for the prior year period.

Net loss for the quarter ended December 31, 2020 was $29.1 million compared to net loss of $24.9 million for the quarter ended December 31, 2019.

Cash and cash equivalents at December 31, 2020 were $486.8 million.


https://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-plc-reports-fourth-quarter-and-year-end-2020

Gwph and Rbii. Looks the same

Congratulations

7 billion


Gwph

https://www.otcmarkets.com/stock/GWPH/profile

Better Buy: Medical Marijuana vs. GW Pharmaceuticals
$GWPH vs $MJNA

https://www.fool.com/investing/2019/04/03/better-buy-medical-marijuana-vs-gw-pharmaceuticals.aspx

Congratulations to the longs of all longs!!!

I will and I will add. This is just the beginning.

Didn't see this coming. Had a limit order to sell a few shares @ $180. Got filled @ $214.

Boom! What a great day

This is worth at least 20 billion easily but is that too greedy? Will you hang onto your jazz shares?

This is great news we held and were patient and now we get the rewards NICE $$$$. I have one other stock that I think will show the same if not better returns.They have a Medicinal MJ part of the company.
PharmaCyte’s major competitors for the development of Cannabis-based treatments for cancer are Cannabis Science, Inc. (“CSI”) and GW Pharmaceuticals, Plc. (“GWP”). CSI plans to use complex extracts of Cannabis to develop treatments for basal and squamous cell carcinomas and Kaposi’s sarcoma. GWP is developing a product portfolio of cannabinoid-based prescription medicines.

PharmaCyte’s Cannabinoid Therapy

PharmaCyte acquired from Austrianova an exclusive, worldwide license to use the Cell-in-a-Box® technology in combination with genetically modified non-stem cell lines which are designed to activate cannabinoid molecules for development of treatments for diseases and their related symptoms. In contrast to the work being done by our competitors, we plan to combine the Cell-in-a-Box® live cell encapsulation technology with cannabinoids to develop a unique therapy for difficult-to-treat and deadly forms of cancer, such as brain cancer. Some cannabinoids are prodrugs that must be converted into their cancer killing form. These prodrugs will be used with the Cell-in-a-Box® technology in ways that optimize their anticancer properties while minimizing or even eliminating adverse side effects that normally occur with chemotherapy to treat cancer.

We plan to use cannabinoids (chemical constituents of the Cannabis plant) to develop therapies for cancer, with the initial target being brain cancer. We are focusing on developing specific therapies based on carefully chosen molecules rather than using complex Cannabis extracts. Targeted cannabinoid-based chemotherapy utilizing the Cell-in-a-Box® technology offers a “green” approach to treating solid-tumor malignancies. Here, the methodology of placing a target in proximity to the tumor so that a cancer prodrug can be activated there mimics our efforts with LAPC except that in this case the cancer prodrug will be cannabinoid-derived.

To further our Cannabis therapy development plans, we entered into a Research Agreement with the University of Northern Colorado. The initial goal of the ongoing research was to develop methods for the identification, separation and quantification of constituents of Cannabis (some of which are prodrugs) that may be used in combination with the Cell-in-a-Box® technology to treat cancer; this has been accomplished. Subsequent studies have been undertaken to identify the appropriate cell type that can convert the selected cannabinoid prodrugs into metabolites with anticancer activity. Once identified, the genetically modified cells that will produce the appropriate enzyme to convert that prodrug will be encapsulated using the Cell-in-a-Box® technology. The encapsulated cells and cannabinoid prodrugs identified by these studies will then be combined and used for future studies to evaluate their anticancer effectiveness.

We plan to focus initially on developing specific therapies based on carefully chosen cannabinoid molecules rather than using complex Cannabis extracts. An understanding of the chemical and biochemical processes involved in the interaction of substances derived from Cannabis with live cell encapsulation provides the opportunity to develop targeted “green” approaches to treating cancers, such as pancreatic, brain, breast and prostate, among others. We believe we are in a unique position among medical Cannabis and pharmaceutical companies to develop cannabinoid-based therapies utilizing our proprietary Cell-in-a-Box® live-cell encapsulation technology as the platform.

Congrats all Longs! Now let’s see if another player comes in higher before the deal closes later this year.

HALTED. GETTING BOUGHT. 220 adr

$gwph $152.47 ^ 4.47 (3.02%)
Volume: 309,284 @01/29/21 7:57:38 PM EST

Better Buy: Medical Marijuana vs. GW Pharmaceuticals
$GWPH vs $MJNA

https://www.fool.com/investing/2019/04/03/better-buy-medical-marijuana-vs-gw-pharmaceuticals.aspx

GW Pharmaceuticals Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones

- Total preliminary net product sales of approximately $148 million for the fourth quarter and approximately $526 million for the full year -
- Total Epidiolex® preliminary net product sales of approximately $144 million for the fourth quarter and approximately $510 million for the full year –
- Pivotal US clinical program for nabiximols in MS spasticity underway. Initial data expected in 2021 -

LONDON and CARLSBAD, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full year 2020 and key priorities for 2021. Justin Gover, GW’s Chief Executive Officer, expects to discuss these updates as part of a webcast presentation at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12th at 10:00 a.m. ET.

https://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-provides-preliminary-fourth-quarter-and-full

$gwph $116.25 ^ 1.04 (0.90%)
Volume: 277,633 @01/05/21 7:46:06 PM EST

$gwph $120.43 v -3.83 (-3.08%)
Volume: 312,382 @12/11/20 6:52:25 PM EST

What’s looking good? This has been a lame performer with all the shares getting sold into it.

Still looking great!
Good luck everyone $GWPH

Trimming my position a little today.

"There are the two cannabis-based medications licensed for use on the NHS. These are Sativex: a mouth spray that contains CBD and THC, for spasticity related to multiple sclerosis; and Epidiolex, an oil containing CBD treatment for those with treatment-resistant epilepsy."

An article today about private clinics in the UK prescribing cannabis-based medications...

https://www.dailymail.co.uk/health/article-9002845/The-Harley-Street-doctors-charging-cannabis-treatments.html

An article from a year and a half ago? Really?

$MJNA vs $GWPH https://www.fool.com/investing/2019/04/03/better-buy-medical-marijuana-vs-gw-pharmaceuticals.aspx

Chugging along! Monsterous move up over the past two weeks!

"Institutional investors and hedge funds own 80.52% of the company’s stock"
thanks, AllGold818.

GW Pharmaceuticals plc (NASDAQ:GWPH) Shares Acquired by Raymond James Financial Services Advisors Inc.




https://www.modernreaders.com/news/2020/11/19/gw-pharmaceuticals-plc-nasdaqgwph-shares-acquired-by-raymond-james-financial-services-advisors-inc.html



GW Pharmaceuticals Plc ADS (GWPH)

Fung where ya been

Your way up now! :)

Still going up. What a nice run after that two months of downward movement.

$gwph $118.8 ^ 1.08 (0.92%)
Volume: 429,144 @11/13/20 7:50:38 PM EST
Bid Ask Day's Range
118.9 122.11 118.1422 - 120.63
GWPH Detailed Quote

$gwph $117.41 ^ 2.77 (2.42%)
Volume: 551,759 @11/09/20 4:01:16 PM EST

BREAKING NEWS: $GWPH Is Innovative Industrial Properties a Buy After Earnings?

Innovative Industrial Properties (IIPR) reported its latest financial results this week and they were spectacular. Learn what this means for the company and if you should consider buying the stock. Cannabis investors got great news earlier in the week, as GW Pharmaceuticals ( GWPH ) ...

Read the whole news GWPH - Is Innovative Industrial Properties a Buy After Earnings?

NEWS: $GWPH GW Pharmaceuticals PLC (GWPH) Q3 2020 Earnings Call Transcript

Image source: The Motley Fool. GW Pharmaceuticals PLC (NASDAQ: GWPH) Q3 2020 Earnings Call Nov 3, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: GW Pharmaceuticals PLC (GWPH) Q3 2020 Earnings Call Transcript

Read the whole news GWPH - GW Pharmaceuticals PLC (GWPH) Q3 2020 Earnings Call Transcript

+20% on the day! Woohoo :)

NEWS: $GWPH Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 490

Delta, Kelowna, BC - November 3, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus ins...

Find out more GWPH - Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 490

GW Pharmaceuticals stock set to rally after Phase 3 trial of MS treatment to start, after COVID-19-related delay

https://www.marketwatch.com/story/gw-pharmaceuticals-stock-set-to-rally-after-phase-3-trial-of-ms-treatment-to-start-after-covid-19-related-delay-2020-11-03

Breaking News: $GWPH GW Pharmaceuticals Initiates Phase 3 Trial for Multiple Sclerosis Drug

GW Pharmaceuticals (NASDAQ: GWPH) announced today that it is starting up its phase 3 trial for nabiximols, an oral spray for patients who have spasticity associated with multiple sclerosis (MS). Nabiximols is a botanical medicine derived from cannabis plants. The drug, sold as Sativ...

Find out more GWPH - GW Pharmaceuticals Initiates Phase 3 Trial for Multiple Sclerosis Drug

JUST IN: $GWPH How GW Pharmaceuticals Blew Away Expectations With Its Q3 Results

You might think that GW Pharmaceuticals (NASDAQ: GWPH) has had a lot of bad news in 2020 if you looked only at its stock performance. That isn't the case, though. The company has won key regulatory approvals and delivered solid revenue growth -- at least so far this year. GW's g...

Find out more GWPH - How GW Pharmaceuticals Blew Away Expectations With Its Q3 Results

Just In: $GWPH GW Pharmaceuticals Stock Pops As Earnings Beat Estimates

GW Pharmaceuticals plc (Nasdaq: GWPH) stock was rising over 6% in early trading as the company delivered solid third-quarter results.  The company reported total revenue of $137.1 million for the quarter ending September 30, 2020, a big jump over the $91.0 million for the sam...

In case you are interested GWPH - GW Pharmaceuticals Stock Pops As Earnings Beat Estimates

Breaking News: $GWPH GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress

- Total revenue increased 51 percent to $ 137.1 million – - Epidiolex for seizures associated with TSC launch ed in the U.S. - - Nabiximols Phase 3 program in MS spasticity now recruiting - - Conferen...

Find out more GWPH - GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress